Sociedad Americana de Hirudoterapia

Duplication of the Antistasin-Like Structure Resulted in a New Anticoagulant Protein in the Medicinal Leech

Basic science / preclinical published in Biomolecules (2026)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: In vitro / laboratoryGenómica y proteómicaFarmacología salivalDesarrollo de fármacosBrovina KA et al. · Biomolecules, 2026

Abstract

Blood-sucking organisms produce various anticoagulant proteins that prevent blood clotting in their prey. Even in well-studied species like Hirudo medicinalis, many such proteins remain unidentified. We previously described a novel cysteine-rich anticoagulant (CRA), a distant homolog of antistasin. Later, we discovered another, much larger homolog in the medicinal leech. Its amino acid sequence is also highly cysteine-rich. Analysis of cysteine patterns showed four antistasin-like domain motifs, with one of them strongly disrupted. Since both antistasin and CRA contain two such domains, the new protein represents a duplicated antistasin-like structure. We cloned its cDNA, expressed the recombinant protein in Escherichia coli, purified it by metal-chelate chromatography, refolded it, and tested its anticoagulant properties. Using standard clinical assays-activated partial thromboplastin time, prothrombin time, and thrombin time-we found that the protein inhibited coagulation in all tests, though to varying degrees. These findings suggest that different antistasin-like anticoagulants in the leech enable it to block both intrinsic and extrinsic coagulation pathways, while hirudin inhibits the final step of clot formation. The combination of different anticoagulant proteins allows the leech to effectively prevent the prey's blood from clotting during feeding.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsAnticoagulantsHirudo medicinalisAmino Acid SequenceBlood CoagulationRecombinant ProteinsLeechesCloning, MolecularEscherichia coli

Resumen

Cloning, expression, and functional characterization of a new Hirudo medicinalis anticoagulant protein with four antistasin-like domain motifs, demonstrating inhibition of both intrinsic and extrinsic coagulation pathways in clinical assays (APTT, PT, TT).

Por qué esto importa para la hirudoterapia

This study identified and characterized a novel cysteine-rich anticoagulant protein from the medicinal leech Hirudo medicinalis, representing a duplicated antistasin-like structure with four domain motifs. The recombinant protein, expressed in Escherichia coli, inhibited coagulation in activated partial thromboplastin time, prothrombin time, and thrombin time assays, suggesting it blocks both intrinsic and extrinsic pathways—complementing hirudin's inhibition of the final common step. This is directly relevant to ASH's domain, as it expands the known repertoire of leech salivary anticoagulants. However, the functional characterization is limited to in vitro clinical coagulation assays, and no in vivo, clinical, or whole-organism hirudotherapy data are presented.

Citación

Duplication of the Antistasin-Like Structure Resulted in a New Anticoagulant Protein in the Medicinal Leech.

Brovina KA et al. · Biomolecules, 2026

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.